MLAB (Life Sciences Tools & Services) Stock Valuation & Fair Value Quality business with a solid forward outlook
MLAB (Life Sciences Tools & Services) trades at a blended P/E of 8.8, about 65% below its historical normal valuation, with a forward growth estimate of 4.2% and a PEG of 2.06. Analysts' one-year estimates have been hit 27% of the time.
Valuation flags
- Low growth forecast
Frequently asked questions
Is MLAB overvalued?
At a blended P/E of 8.8 versus its historical normal P/E of 25.2, MLAB trades about 65% below its typical valuation, with a PEG of 2.06 on 4.2% forward growth. tickerseer currently rates it quality business with a solid forward outlook.
What is MLAB's fair value and PEG?
MLAB trades at a blended P/E of 8.8 against a historical normal P/E of 25.2, a PEG of 2.06, and a forward growth estimate of 4.2%.
Has tickerseer's rating of MLAB changed?
tickerseer's rating has been quality business with a solid forward outlook since 2026-08-07.
Industry: Life Sciences Tools & Services. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.
Get the free weekly earnings preview
One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.
It's free, and you can unsubscribe any time. Educational content, not investment advice.